MEK inhibition suppresses metastatic progression of KRAS-mutated gastric cancer

被引：0
|
作者：
Yamasaki, Juntaro [1 ]
Otsuki, Yuji [1 ]
Masuda, Kenta [2 ]
Saya, Hideyuki [3 ]
Nagano, Osamu [1 ]
机构：
[1] Keio Univ, Sch Med, Div Gene Regulat, IAMR, Keio, Japan
[2] Keio Univ, Dept Obstet Gynecol, Sch Med, Keio, Japan
[3] Fujita Hlth Univ, Div Gene Reg, Fujita Canc Ctr, Toyoake, Aichi, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-1140
引用
收藏
页码：377 / 377
页数：1
相关论文
共 50 条
  • [21] Basroparib overcomes acquired resistance to MEK inhibitors by inhibiting Wnt-mediated cancer stemness in KRAS-mutated colorectal cancer
    Kwon, Young-Ju
    Kim, Dong Young
    Kim, Uk-Il
    Kim, Song Hyun
    Kim, Ye-hyun
    Kim, Kyungjin
    Kim, Jae-Sung
    BIOCHEMICAL PHARMACOLOGY, 2025, 235
  • [22] BRAF Inhibitor-Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition
    Andrews, Miles C.
    Behren, Andreas
    Chionh, Fiona
    Mariadason, John
    Vella, Laura J.
    Do, Hongdo
    Dobrovic, Alexander
    Tebbutt, Niall
    Cebon, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (35) : E448 - E451
  • [23] Comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
    Tougeron, D.
    Laurent-Puig, P.
    Zaanan, A.
    BRITISH JOURNAL OF CANCER, 2014, 111 (12) : 2379 - 2380
  • [24] Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’
    D Tougeron
    P Laurent-Puig
    A Zaanan
    British Journal of Cancer, 2014, 111 : 2379 - 2380
  • [25] Realities of KRAS-mutated non-small cell lung cancer
    Min, Young Joo
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2017, 32 (03): : 442 - 442
  • [26] Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer
    Jiffry, Jeeshan
    Thavornwatanayong, Thongthai
    Rao, Devika
    Fogel, Elisha J.
    Saytoo, Durvanand
    Nahata, Rishika
    Guzik, Hillary
    Chaudhary, Imran
    Augustine, Titto
    Goel, Sanjay
    Maitra, Radhashree
    CLINICAL CANCER RESEARCH, 2021, 27 (03) : 865 - 876
  • [27] SELUMETINIB, A MEK INHIBITOR, SUPPRESSES ACTIVE KRAS INDUCED-METAPLASIA PROGRESSION TOWARD GASTRIC NEOPLASIA
    Choi, Eunyoung
    Engevik, Amy C.
    Goldenring, James R.
    GASTROENTEROLOGY, 2018, 154 (06) : S121 - S122
  • [28] Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’
    K-L G Spindler
    N Pallisgaard
    R F Andersen
    A Jakobsen
    British Journal of Cancer, 2014, 111 : 2380 - 2380
  • [29] Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer
    Rossi, Sabrina
    Pagliaro, Arianna
    Finocchiaro, Giovanna
    Marinello, Arianna
    Giordano, Laura
    Bria, Emilio
    Stefani, Alessio
    Vitale, Antonio
    Toschi, Luca
    D'Argento, Ettore
    Santoro, Armando
    FUTURE ONCOLOGY, 2024, 20 (07) : 373 - 380
  • [30] Response to comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
    Spindler, K-L G.
    Pallisgaard, N.
    Andersen, R. F.
    Jakobsen, A.
    BRITISH JOURNAL OF CANCER, 2014, 111 (12) : 2380 - 2380
12345